Hysterectomy with salpingectomy versus hysterectomy alone
Referencias
Additional references
Committee on Gynecologic Practice. Committee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstetrics & Gynecology 2015;125(1):279‐81.
Bolton KL, Chenevix‐Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Assosciation Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA January 25, 2012;307(4):382‐390.
Chen F, Gaitskell K, Garcia MJ, Albukhari A, Tsaltas J, Ahmed AA. Serous tubal intraepithelial carcinomas associated with high‐grade serous ovarian carcinomas: a systematic review. BJOG 2017;124(6):872‐8. [PUBMED: 28218502]
Veritas Health Innovation. Covidence. Version accessed xxx. Melbourne: Veritas Health Innovation.
Depmann J, Eijkemans MJC, Broer SL, Scheffer GJ, van Rooij IA, Laven JS, et al. Does anti‐Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study. Human Reproduction 2016;31(7):1579‐87.
Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertily and Sterility 2013;99(6):1724‐8.
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed xxx. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Higgins JP, White IR, Anzures‐Cabrera J. Meta‐analysis of skewed data: combining results reported on log‐transformed or raw scales. Statistics in Medicine 2008;27(29):6072‐92.
Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta‐analysis of clinical trials. Clinical Trials 2008;5(3):225‐39.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk‐reducing salpingo‐oophorectomy for the prevention of BRCA1‐ and BRCA2‐associated breast and gynecologic cancer: a multicenter, prospective study. Journal of Clinical Oncology 2008;26(8):1331‐7. [PUBMED: 18268356]
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. The American Journal of Surgical Pathology 2007;31(2):161‐9. [PUBMED: 17255760]
Long Roche KC, Abu‐Rustum NR, Nourmoussavi M, Zivanovic O. Risk‐reducing salpingectomy: Let us be opportunistic. Cancer 2017;123(10):1714‐20. [PUBMED: 28334425]
Mytton J, Evison F, Chilton PJ, Lilford RJ. Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy in premenopausal patients with benign disease: study using routine data and data linkage. BMJ (Clinical research ed.) 2017;356:j372. [PUBMED: 28167486]
Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long‐term health outcomes in the nurses' health study. Obstetrics and Gynecology 2009;113(5):1027‐37. [PUBMED: 19384117]
Perez‐Lopez FR, Ceausu I, Depypere H, Kehoe S, Lambrinoudaki I, Mueck A, et al. Interventions to reduce the risk of ovarian and fallopian tube cancer: a European Menopause and Andropause Society Postition Statement. Maturitas 2017;100:86‐91. [PUBMED: 28389043]
Piek JMJ, van Diest PJ, Zweemer RP, Jansen JW, Poort‐Keesom RJJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Journal of Pathology 2001;195:451‐456.
Piek JMJ, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RHM. Tubal ligation and risk of ovarian cancer. The Lancet September 8, 2001;358:844.
Piek JMJ, Verheijen RHM, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2‐related ovarian cancers are of tubal origin: a hypothesis. Gynecologic Oncology 2003;90(2):491.
Royal College of Obstetricians and Gynaecologists. The distal fallopian tube as the origin of non‐uterine pelvic high‐grade serous carcinomas. Scientific impact paper no. 44. November 2014. www.rcog.org.uk/globalassets/documents/guidelines/scientific‐impact‐papers/sip44hgscs.pdf (accessed 25 September 2017).
Rebbeck TR, Kauff ND, Domchek SM. Meta‐analysis of risk reduction estimates associated with risk‐reducing salpingo‐oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute 2009;101(2):80‐7. [PUBMED: 19141781]
Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ. Survival patterns after oophorectomy in premenopausal women: a population‐based cohort study. The Lancet. Oncology 2006;7(10):821‐8. [PUBMED: 17012044]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians January/February 2017;67(1):7‐30.
Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical research ed.) 2016;355:i4919. [PUBMED: 27733354]
van Rooij IAJ, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JDF, de Jong FH, et al. Serum antimüllerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertility and Sterility 2005;83(4):979‐87.
